dapivirine has been researched along with chloroquine in 1 studies
| Studies (dapivirine) | Trials (dapivirine) | Recent Studies (post-2010) (dapivirine) | Studies (chloroquine) | Trials (chloroquine) | Recent Studies (post-2010) (chloroquine) |
|---|---|---|---|---|---|
| 196 | 64 | 160 | 16,405 | 763 | 4,029 |
| Protein | Taxonomy | dapivirine (IC50) | chloroquine (IC50) |
|---|---|---|---|
| glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase | Plasmodium berghei | 43 | |
| Spike glycoprotein | Betacoronavirus England 1 | 5.47 | |
| Replicase polyprotein 1ab | Betacoronavirus England 1 | 5.47 | |
| Transmembrane protease serine 2 | Homo sapiens (human) | 5.47 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0301 | |
| Amyloid-beta precursor protein | Homo sapiens (human) | 7 | |
| Histidine-rich protein PFHRP-II | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2383 | |
| Procathepsin L | Homo sapiens (human) | 5.47 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Replicase polyprotein 1ab | Human coronavirus 229E | 5.47 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Spike glycoprotein | Severe acute respiratory syndrome coronavirus 2 | 3.58 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 6.375 | |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | 1.5 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.27 | |
| Beta-secretase 1 | Homo sapiens (human) | 7 | |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | 5.47 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 2.503 | |
| Angiotensin-converting enzyme 2 | Homo sapiens (human) | 6.235 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.02 | |
| Cysteine proteinase falcipain 2a | Plasmodium falciparum (malaria parasite P. falciparum) | 0.2 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ariën, KK; Augustyns, K; Cos, P; Dirié, B; Heeres, J; Joossens, J; Lewi, PJ; Lyssens, S; Maes, L; Michiels, J; Van der Veken, P; Vanham, G; Venkatraj, M | 1 |
1 other study(ies) available for dapivirine and chloroquine
| Article | Year |
|---|---|
From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds.
Topics: Anti-HIV Agents; Cell Line; Cell Survival; Dose-Response Relationship, Drug; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Structure; Parasitic Sensitivity Tests; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Trypanocidal Agents; Trypanosoma brucei brucei; Trypanosoma brucei rhodesiense | 2014 |